

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VIVA BIOTECH HOLDINGS

维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

SUPPLEMENTAL ANNOUNCEMENT

REGARDING THE ANNOUNCEMENT PUBLISHED ON MARCH 16, 2021

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, collectively referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the Company’s announcement dated March 16, 2021 in relation to the Company’s profit warning (the “**March 16 Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meaning as those defined in the March 16 Announcement.

The board of directors of the Company (the “**Board**”) wishes to further inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group and information currently available, for the year ended December 31, 2020 (the “**Year**”), the net loss expected to be recorded by the Group during the Year will be no higher than RMB400 million, as compared to the net profit of approximately RMB266 million for the year ended December 31, 2019. As disclosed in the March 16 Announcement and based on the information currently available, the Board considers that the significant net loss is mainly attributable to an extraordinary loss of approximately RMB600 million in relation to the fair value loss of the Convertible Bonds under the IFRS. Please refer to the March 16 Announcement for further details.

The Company is in the process of preparing the consolidated financial results of the Group for the Year. The information contained in this supplemental announcement is based on a preliminary assessment of the unaudited consolidated management accounts currently available to the Company, which is subject to finalization and other potential adjustments (if any) and has not been audited or reviewed by the Company’s auditors or the audit committee of the Company. Details of the Group’s performance will be disclosed in the annual results announcement of the Company for the Year, which is expected to be published by the end of March 2021.

Shareholders and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, March 19, 2021

As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; a Non-executive Director, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.